Impact of JACIE accreditation on safety of patient care: healthcare providers perspective from a tertiary care stem cell transplant center in Saudi Arabia
Mohamed Bayoumy,Ahlam Almasari,Amany Orabe,Nahla Shihata,Bassim AlBeirouti,Naif I. AlJohani,Binyam Usman,Zayed Alzahrani,Amal AlSeraihy,Ibraheem Abosoudah,Alanoud AbualSaud,Wasil Jastaniah
DOI: https://doi.org/10.1038/s41409-024-02387-z
2024-09-29
Bone Marrow Transplantation
Abstract:Hematopoietic stem cell transplantation (HSCT), is a therapeutic modality often offered as a curative option for several malignant and non-malignant indications. The main aim of the JACIE (Joint Accreditation Committee for the International Society for Cellular Therapy (ISCT) Europe and the European Group for Blood and Marrow Transplantation (EBMT)) accreditation is to promote highest quality of care (QoC) to patients through an internationally recognized set of quality standards for best practices [1,2,3,4]. The HSCT program at King Faisal Specialist Hospital and Research Centre, Jeddah (KFSH&RC-J), Saudi Arabia, was awarded the JACIE accreditation in July 2020. Multiple studies have shown positive impact of the JACIE accreditation [5,6,7,8,9]; however, none has objectively investigated the healthcare providers (HCPs) perception on JACIE as a tool for improving QoC and patient safety. In 2023, we conducted a cross-sectional, descriptive, survey-based study to measure impact of JACIE accreditation. The study was approved by the institutional review board (IRB) (IRB# IRB 2021–22) and the main aim of the study was to determine impact of the JACIE accreditation on patient safety from a HCPs perception.
oncology,immunology,hematology,transplantation